HAYA Therapeutics secures USD 65M to advance RNA-guided therapies for chronic and age-related diseases

Swiss biotech company HAYA Therapeutics has raised USD 65 million in Series A Funding to accelerate the clinical development of its RNA-guided therapeutics platform. The investment supports the company's lead candidate, HTX-001, aimed at treating heart failure, and extends to expanding its pipeline across other chronic and age-related diseases.

Proceeds from the USD 65 million round will fund clinical trials for HTX-001, HAYA Therapeutics's lead candidate for non-obstructive hypertrophic cardiomyopathy (nHCM), and support pipeline expansion into conditions such as pulmonary fibrosis and obesity.

HAYA's platform targets the regulatory genome—the non-coding 98% DNA governing gene expression. By combining functional genomics with machine learning, the company identifies and reprograms disease-driving cell states with high precision.

The round was led by Sofinnova Partners and Earlybird Venture Capital, with participation from Eli Lilly and Company, ATHOS, +ND Capital, Alexandria Venture Investments and LifeLink Ventures, with additional support from existing investors Apollo Health Ventures, Longview Ventures (an affiliate of Broadview Ventures), 4see ventures, BERNINA Bioinvest and Schroders Capital. HAYA also recently announced a strategic partnership with Lilly focused on RNA-based targets in metabolic disorders.

The Biotech company was ranked among the TOP 100 Swiss Startups for 5 consecutive years, won Venture Kick, and participated in Venture Leaders Biotech.


HAYA's team